NYSE: NVONovo Nordisk A S Stock Forecast, Predictions & Price Target
Analyst price target for NVO
Based on 2 analysts offering 12 month price targets for Novo Nordisk A S.
Min Forecast
$72.00+1.62%
Avg Forecast
$72.35+2.12%
Max Forecast
$72.70+2.61%
Should I buy or sell NVO stock?
Hold
Strong Buy
2 analysts 25.00%
Buy
0 analysts 0.00%
Hold
5 analysts 62.50%
Sell
1 analysts 12.50%
Strong Sell
0 analysts 0.00%
Forecast return on equity
Is NVO forecast to generate an efficient return?
Company
13.00%
Industry
28.63%
Market
-1.38%
NVO's Return on Equity is forecast to be low in 4 years (13.00%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is NVO forecast to generate an efficient return on assets?
Company
5.73%
Industry
4.26%
Market
11.51%
NVO is forecast to generate higher Return on Assets (5.73%) than the US Biotechnology industry average (4.26%)
Forecast
NVO earnings per share forecast
What is NVO's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$2.72-84.56%
Avg 2 year Forecast
$2.95-83.27%
Avg 3 year Forecast
$3.21-81.81%
NVO's earnings are forecast to grow at a rate of -43.39% per year, which is not exceptional
Forecast
NVO revenue forecast
What is NVO's revenue in the next 3 years based on estimates from 1 analysts?
Avg 1 year Forecast
$19.0B-84.99%
Avg 2 year Forecast
$19.9B-84.27%
Avg 3 year Forecast
$21.7B-82.85%
NVO's revenue is forecast to grow at a rate of -44.44% per year, which is not exceptional
Forecast
NVO earnings growth forecast
How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
-43.39%
Industry
-2.23%
Market
14.64%
NVO's earnings are forecast to grow slower (-43.39% per year) than the US Biotechnology industry average (-2.23%)
Forecast
NVO's earnings are forecast to grow slower (-43.39% per year) than the US market average (14.64%)
Forecast
NVO revenue growth forecast
How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
-44.44%
Industry
43.08%
Market
5.53%
NVO's revenues are forecast to grow slower (-44.44% per year) than the US Biotechnology industry average (43.08%)
Forecast
NVO's revenues are forecast to grow slower (-44.44% per year) than the US market average (5.53%)
Forecast
Novo Nordisk A S Stock Forecast FAQ
Is Novo Nordisk A S Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 8 Wall Street analysts covering (NYSE: NVO) stock is to Hold NVO stock.
Out of 8 analysts, 2 (25.00%) are recommending NVO as a Strong Buy, 0 (0.00%) are recommending NVO as a Buy, 5 (62.50%) are recommending NVO as a Hold, 1 (12.50%) are recommending NVO as a Sell, and 0 (0.00%) are recommending NVO as a Strong Sell.
What is NVO's Price Target?
According to 2 Wall Street analysts that have issued a 1 year NVO price target, the average NVO price target is $72.35, with the highest NVO stock price forecast at $72.70 and the lowest NVO stock price forecast at $72.00.
On average, Wall Street analysts predict that Novo Nordisk A S's share price could reach $72.35 by Oct 13, 2021. The average Novo Nordisk A S stock price prediction forecasts a potential upside of 2.12% from the current NVO share price of $70.85.
What is NVO's earnings growth forecast for 2020-2022?
(NYSE: NVO) Novo Nordisk A S's forecast annual earnings growth rate of -43.39% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of -2.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.64%.
Novo Nordisk A S's earnings in 2020 is $41,433,000,000.On average, 4 Wall Street analysts forecast NVO's earnings for 2020 to be $6,413,488,000, with the lowest NVO earnings forecast at $6,272,014,000, and the highest NVO earnings forecast at $6,696,436,000. On average, 4 Wall Street analysts forecast NVO's earnings for 2021 to be $6,949,910,250, with the lowest NVO earnings forecast at $6,507,804,000, and the highest NVO earnings forecast at $7,215,174,000.
In 2022, NVO is forecast to generate $7,557,069,500 in earnings, with the lowest earnings forecast at $7,285,911,000 and the highest earnings forecast at $7,828,228,000.
What is NVO's revenue growth forecast for 2020-2022?
(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of -44.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 43.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.53%.
Novo Nordisk A S's revenue in 2020 is $126,575,000,000.On average, 1 Wall Street analysts forecast NVO's revenue for 2020 to be $44,806,584,225,000, with the lowest NVO revenue forecast at $44,806,584,225,000, and the highest NVO revenue forecast at $44,806,584,225,000. On average, 2 Wall Street analysts forecast NVO's revenue for 2021 to be $46,942,759,098,500, with the lowest NVO revenue forecast at $46,354,663,470,000, and the highest NVO revenue forecast at $47,530,854,727,000.
In 2022, NVO is forecast to generate $51,185,493,621,500 in revenue, with the lowest revenue forecast at $50,251,564,800,000 and the highest revenue forecast at $52,119,422,443,000.
What is NVO's Earnings Per Share (EPS) forecast for 2020-2022?
(NYSE: NVO) Novo Nordisk A S's current Earnings Per Share (EPS) is $17.62. On average, analysts forecast that NVO's EPS will be $2.72 for 2020, with the lowest EPS forecast at $2.66, and the highest EPS forecast at $2.84. On average, analysts forecast that NVO's EPS will be $2.95 for 2021, with the lowest EPS forecast at $2.76, and the highest EPS forecast at $3.06. In 2022, NVO's EPS is forecast to hit $3.21 (min: $3.09, max: $3.32).
What is NVO's forecast return on equity (ROE) for 2020-2023?
(NYSE: NVO) forecast ROE is 13.00%, which is considered weak.
What is NVO's forecast return on assets (ROA) for 2020-2023?
(NYSE: NVO) forecast ROA is 5.73%, which is higher than the forecast US Biotechnology industry average of 4.26%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
